王晖,曹卉,高东田,周雨笋.重症监护室鲍曼不动杆菌感染及药敏试验研究[J].济宁医学院学报,2011,(2):102-103,147 |
重症监护室鲍曼不动杆菌感染及药敏试验研究 |
Investigation and analysis of infection stuation of acinetobacter baumanniii in ICU of comprehensive hospital |
投稿时间:2011-02-27 |
DOI:10.3969/j.issn.1000-9760.2011.02.009 |
中文关键词: 鲍曼不动杆菌|重症监护室|感染状况 |
英文关键词: Acinetobacter baumanniii|intensive care unit|infection stuation |
基金项目: |
作者 | 单位 | 王晖 | 济宁医学院基础医学与法医学院, 山东济宁 272067 | 曹卉 | 济宁医学院基础医学与法医学院, 山东济宁 272067 | 高东田 | 济宁医学院附属医院, 山东济宁 272029 | 周雨笋 | 济宁医学院学生, 山东济宁 272067 |
|
摘要点击次数: 5534 |
全文下载次数: 1105 |
中文摘要: |
目的 了解重症监护室(ICU)患者鲍曼不动杆菌感染及耐药情况,指导临床医师选择有效抗生素进行抗感染治疗,控制院内感染的发生。方法 2008年1月至2010年1月期间自重症监护室患者分离鲍曼不动杆菌,细菌鉴定用VITEK-GNI+,药敏试验采用K-B法。结果 分离出172株鲍曼不动杆菌,主要来自呼吸道感染患者痰液,占87.21%,以综合性重症监护室鲍曼不动杆菌的检出率为最高。药敏结果显示鲍曼不动杆菌对米诺环素、亚胺培南、头孢哌酮/舒巴坦、哌拉西林/他唑巴坦及左氧氟沙星的耐药率低,分别为1.32%,5.88%、4.71%、17.65%和23.53%,而对其他抗生素有较强的耐药性。结论 鲍曼不动杆菌是重症监护室呼吸道感染的常见菌,且耐药性高,建议选用米诺环素、亚胺培南、头孢哌酮/舒巴坦、哌拉西林/他唑巴坦和左氧氟沙星治疗鲍曼不动杆菌的感染。 |
英文摘要: |
Objective To investigate the Acinetobacter baumannii infection and drug resistance of ICU patients and instruct clinician to choose the effective antibiotic for the anti-infection treatment in order to control the occurrence of nosocomial infection.Methods Acinetobacter baumannii strains were isolated from ICU patients during January 2008 to January 2010.VITEK-GNI+ is used for identification of bacteria and K-B method for drug susceptibility test.Results 172 strains of Acinetobacter baumannii was mainly isolated from the sputum in respiratory tract infection of patients and the proportion was 87.21%.The detection rate was the highest in the comprehensive ICU.The rate of drug resistance was low to MH, IPM, SCF, TZP and LEV and the rates were 1.32%, 5.88%, 4.71%, 17.56%, 23.53% respectively.But the rate of drug resistance to many other antibiotic was higher.Conclusion Acinetobacter baumanniii is common in ICU.It can result in respiratory tract infection and has high drug resistance.Detection and analysis of Acinetobacter baumannii have high significance.Therefore, we recommend MH、IPM、SCF、TZP and LEV for the treatment of Acinetobacter baumanniii infections as the first choice. |
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|